5-amino-2-bromo-4-methylbenzonitrile | 1202858-66-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-amino-2-bromo-4-methylbenzonitrile
• CAS: 1202858-66-9
• 化学式: C₈H₇BrN₂
• 分子量: 211.061
• InChiKey: LAHISTKZZXMECZ-UHFFFAOYSA-N

物化性质

• 沸点：
  361.3±42.0 °C(Predicted)
• 密度：
  1.59±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-amino-2-bromo-4-methylbenzonitrile 在 亚硝酸特丁酯 、 三氟化硼乙醚 、 18-冠醚-6 、 potassium acetate 作用下， 以 二氯甲烷 为溶剂， 生成 5-bromo-1H-indazole-6-carbonitrile
  参考文献：
  名称：

  Discovery, Optimization, and Biological Evaluation of 5-(2-(Trifluoromethyl)phenyl)indazoles as a Novel Class of Transient Receptor Potential A1 (TRPA1) Antagonists

  摘要：

  A high throughput screening campaign identified 5-(2-chlorophenyl)indazole compound 4 as an antagonist of the transient receptor potential A1 (TRPA1) ion channel with IC50 = 1.23 μM. Hit to lead medicinal chemistry optimization established the SAR around the indazole ring system, demonstrating that a trifluoromethyl group at the 2-position of the phenyl ring in combination with various substituents at the 6-position of the indazole ring greatly contributed to improvements in vitro activity. Further lead optimization resulted in the identification of compound 31, a potent and selective antagonist of TRPA1 in vitro (IC50 = 0.015 μM), which has moderate oral bioavailability in rodents and demonstrates robust activity in vivo in several rodent models of inflammatory pain.

  DOI：

  10.1021/jm401986p
• 作为产物：
  描述：

  3-氨基-4-甲基苯甲腈 在 N-溴代丁二酰亚胺(NBS) 、 N,N-二甲基甲酰胺 作用下， 以87.5 %的产率得到5-amino-2-bromo-4-methylbenzonitrile
  参考文献：
  名称：

  IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE

  摘要：

  本申请涉及咪唑烷酮衍生物及其医药用途，特别是涉及由一般式(I)表示的嘧啶衍生物，或者其立体异构体、溶剂化物、代谢物、前药、药学上可接受的盐或共晶，包含所述化合物的药物组合物，以及根据本申请的化合物或药物组合物在制备用于治疗癌症的药物中的用途。

  公开号：

  EP4137491A1

文献信息

• PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS
  申请人：Marsilje Thomas H.

  公开号：US20110112063A1

  公开（公告）日：2011-05-12

  The invention provides novel pyrimidine derivatives of formula I and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).

  本发明提供了式I的新型嘧啶衍生物及其制药组合物，以及使用这些化合物的方法。例如，本发明的嘧啶衍生物可用于治疗、改善或预防对IGF-IR或ALK抑制有反应的疾病。
• Compounds and compositions as kinase inhibitors
  申请人：Marsilje Thomas H.

  公开号：US08859574B2

  公开（公告）日：2014-10-14

  The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or analplastic lymphoma kinase (ALK).

  本发明提供了新型嘧啶衍生物及其制药组合物，以及使用这些化合物的方法。例如，本发明的嘧啶衍生物可用于治疗、改善或预防对胰岛素样生长因子（IGF-1R）或无形淋巴瘤激酶（ALK）抑制有反应的疾病。
• COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
  申请人：Marsilje Thomas H.

  公开号：US20130310361A1

  公开（公告）日：2013-11-21

  The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or analplastic lymphoma kinase (ALK).

  本发明提供新型嘧啶衍生物及其药物组合物，以及使用这些化合物的方法。例如，本发明的嘧啶衍生物可用于治疗、改善或预防对胰岛素样生长因子（IGF-1R）或无形淋巴瘤激酶（ALK）抑制有反应的疾病。
• Pyrimidine derivatives as kinase inhibitors
  申请人：Marsilje, III Thomas H.

  公开号：US08519129B2

  公开（公告）日：2013-08-27

  The invention provides novel pyrimidine derivatives of formula I and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).

  该发明提供了公式I的新型嘧啶衍生物及其制药组合物，以及使用这些化合物的方法。例如，该发明的嘧啶衍生物可以用于治疗、改善或预防对IGF-IR或ALK的抑制有反应的情况。
• P38 INHIBITORS AND METHODS OF USE THEREOF
  申请人：Munson Mark C.

  公开号：US20090149443A1

  公开（公告）日：2009-06-11

  Compounds of formula (I): in which A, B, X, Ar 1 , R 8 and R 4 have any of the meanings given in the specification, are inhibitors of p38 useful in the treatment and prevention of various disorders mediated by p38.

  化合物的公式(I)：其中A、B、X、Ar1、R8和R4具有规范中给出的任何含义，是p38的抑制剂，可用于治疗和预防由p38介导的各种疾病。